Antiseizure properties of cannabidiol (CBD) are attenuated in the absence of transient receptor potential vanilloid 1 (TRPV1) receptors (S53.004)
Citation Manager Formats
Make Comment
See Comments

Abstract
Objective: Evaluate effect of CBD upon seizure threshold in wild-type (WT) and TRPV1 knockout (TRPV1−/−) mice.
Background: TRPV1 receptor expression is increased in rodent epilepsy models and temporal lobe epilepsy patients. CBD is a TRPV1 agonist that rapidly desensitizes TRPV1. A pharmaceutical formulation of purified CBD has been shown to reduce seizure frequency in Lennox-Gastaut and Dravet syndrome patients.
Design/Methods: Mice received intraperitoneal CBD (10–200 mg/kg; GW Pharmaceuticals), CBD vehicle (ethanol:kolliphorEL:saline, 1:1:18 ratio) 60 minutes before testing, the TRPV1 antagonist capsazepine (10 mg/kg in 2% DMSO), or diazepam (2.5 mg/kg in saline) 30 minutes before testing (n=12/group). A constant current stimulus (1–300 mA; 0.1 s duration) was delivered via corneal electrodes and mice assessed for tonic hind limb extension. Stimulus intensity was varied by a shock titration method and the current required to produce maximal seizures in 50% of animals tested (CC50) values calculated. Statistical analysis was performed using two-way ANOVA with post-hoc Sidak’s tests. Brain and plasma CBD concentrations were assessed by liquid chromatography/tandem mass spectrometry.
Results: There was a significant interaction between genotype and disease (F(6,154)=24.35; P<0.0001) and main effects of genotype (F(1,154)=169.6; P<0.0001) and treatment (F(6,154)=113.4; P<0.001) upon CC50 which arose from significantly attenuated responses in TRPV1−/− mice to CBD (50 & 100 mg/kg; each P<0.0001), diazepam (P<0.001) and capsazepine (P<0.05) when compared to WT. No significant difference in brain CBD concentrations was noted between WT and TRPV1−/− mice (P>0.05).
Conclusions: CBD dose-dependently increased seizure threshold in WT mice, an effect markedly reduced in TRPV1−/− mice. Brain CBD concentrations were consistent with those required for TRPV1 activation and desensitization, suggesting that CBD’s anticonvulsant effects in acute, generalized seizures are partially mediated via TRPV1 receptor interaction.
Study Supported by:
GW Research Ltd
Disclosure: Dr. Whalley has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with GW PHARMACEUTIALS (EMPLOYMENT). Dr. Whalley holds stock and/or stock options in GW PHARMACEUTICALS, which sponsored research in which Dr. Whalley was involved as an investigator. Dr. Gray has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with GW Pharmaceuticals. Dr. Gray has received compensation for serving on the Board of Directors of GW Pharmaceuticals. Dr. Stott has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with GW Pharmaceuticals. Dr. Stott has received compensation for serving on the Board of Directors of GW Pharmaceuticals. Dr. Stott holds stock and/or stock options in GW Pharmaceuticals, which sponsored research in which Dr. Stott was involved as an investigator. Dr. Jones has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with GW Pharmaceuticals. Dr. Jones has received compensation for serving on the Board of Directors of GW Pharmaceuticals.
Letters: Rapid online correspondence
REQUIREMENTS
If you are uploading a letter concerning an article:
You must have updated your disclosures within six months: http://submit.neurology.org
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Hemiplegic Migraine Associated With PRRT2 Variations A Clinical and Genetic Study
Dr. Robert Shapiro and Dr. Amynah Pradhan
Related Articles
- No related articles found.